The international pharmaceutical trade policies of the BRICS countries and its implications for China
10.3969/j.issn.1674-2982.2024.04.010
- VernacularTitle:金砖五国药物国际贸易政策及对中国的启示
- Author:
Zuo-Kun LIU
1
;
Wang-Yao MA
;
Yi-Wu GU
;
Yu-Yang ZHANG
;
Ji-Yan MA
;
Ming-Fan PANG
;
Yi-Nuo SUN
;
Yang-Mu HUANG
Author Information
1. 北京大学公共卫生学院 北京 100191
- Keywords:
BRICS countries;
Pharmaceutical policy;
International trade;
Global health
- From:
Chinese Journal of Health Policy
2024;17(4):65-71
- CountryChina
- Language:Chinese
-
Abstract:
This study adopted the policy text analysis method,review the historical background of the enactment,aimed to comparatively analyze the international pharmaceutical trade policies of the BRICS countries.The main objectives of the BRICS countries'international pharmaceutical trade policies included ensuring stable and accessible drug supply,expanding exports of domestic products and creating a favorable political environment.For these purposes,Brazil,Russia,and South Africa all ensure drug supply through substantial imports.However,they have also taken measures such as compulsory patent licensing and promoting localization of production by foreign companies to reduce import dependence.India,on the other hand,protects its domestic industry by resisting drug imports to ensure drug supply while simultaneously promoting the export of pharmaceutical products.China continually optimizes approval and data monitoring procedures to align with international standards,creating a favorable trade environment and expanding exports.China should further refine its international pharmaceutical trade policies while ensuring the autonomy of domestic drug research and supply,fostering stronger collaboration within BRICS nations and promoting global access to public healthcare products.
